Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 7/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92531 | 0.77 | MAPT (0.60) | MAPTPOLBLMNARXFP1TP53 | |
| SCHEMBL6834329 | 0.77 | HIF1A (0.60) | MAPTAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL9513479 | 0.75 | MAPT (0.80) | MAPTAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6773122 | 0.75 | TP53 (0.72) | MAPTPOLBLMNARXFP1TP53 | |
| SCHEMBL92533 | 0.75 | MAPT (0.60) | MAPTPOLBLMNATP53SMN1; SMN2 | |
| SCHEMBL92534 | 0.74 | MAPT (0.65) | MAPTPOLBLMNATP53SMN1; SMN2 | |
| SCHEMBL6818060 | 0.74 | AKR1C2 (0.51) | MAPTPOLBAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL1307732 | 0.74 | GFER (0.76) | MAPTAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1308599 | 0.73 | CDK2 (0.61) | MAPTPOLBLMNAAKR1C4AKR1C3 | |
| SCHEMBL7454304 | 0.73 | TP53 (0.57) | MAPTPOLBLMNARXFP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | MAPT 4759/4885POLB 637/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.